Paper 13293-13
Artificial intelligence in urology: combining imaging and clinical data for improved prostate diagnostics
25 January 2025 • 2:50 PM - 3:10 PM PST | Moscone South, Room 301 (Level 3)
Abstract
Recent advancements in computer-aided imaging have significantly improved the detection of prostate morphological alterations and cancer diagnosis. However, the focus on imaging has led to the neglect of other valuable patient-related data. This study explores the potential benefits of combining image data with diverse tabular data, including patient demographics and clinical findings, to maximize diagnostic accuracy. Our research utilized a dataset of 3800 biparametric MR studies from biopsy-naive patients and their respective demographic and clinical data including all available PSA values. We developed and evaluated fusion methodologies that integrate magnetic resonance imaging data with tabular data to assess both binary and multiclass prediction capabilities. Our best-performing fusion model achieved a ROC-AUC of 0.794 and a QWK of 0.464 in multiclass prediction of prostatitis and Gleason scores, significantly outperforming both image-only and tabular data-only approaches. These results demonstrate that the integration of MR imaging with clinical and demographic data significantly enhances predictive precision in prostate cancer diagnosis.
Presenter
Lucas Engelage
Laser-Forschungslabor, Klinikum der Univ. München, Ludwig-Maximilians-Univ. München (Germany), ALTA Klinik GmbH (Germany)
Lucas Engelage is a dedicated researcher with 4 years of experience in the field of urological diagnostics and treatment. His work focuses on advancing prostate cancer detection and management through innovative technologies. Engelage has been at the forefront of developing an artificial intelligence system capable of detecting prostate cancer in MRI images, significantly improving diagnostic accuracy and efficiency. In parallel, he has been instrumental in the development of a novel PSA test that utilizes dry capillary blood, potentially revolutionizing the ease and accessibility of prostate cancer screening. His research also extends to therapeutic innovations, including work on the TULSA PRO therapy, a minimally invasive treatment for prostate cancer. Engelage's multifaceted approach to urological research demonstrates his commitment to improving patient outcomes through the integration of cutting-edge technologies in diagnostics and treatment.